Your browser doesn't support javascript.
loading
[Systematic review and Meta-analysis on efficacy and safety of Yangxue Qingnao Granules in treatment of migraine].
Lin, Lei; Min, Jia; Yun-Ling, Zhang; Yan, L U; Xing, Liao; Xiao, Liang; Jing-Jing, Wei; Qian, Chen; Guo-Jing, F U.
Afiliación
  • Lin L; Graduate School, Beijing University of Chinese Medicine Beijing 100029, China Center for Evidence-based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
  • Min J; Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
  • Yun-Ling Z; Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
  • Yan LU; Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
  • Xing L; Center for Evidence-based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
  • Xiao L; Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
  • Jing-Jing W; Graduate School, Beijing University of Chinese Medicine Beijing 100029, China Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
  • Qian C; Graduate School, Beijing University of Chinese Medicine Beijing 100029, China.
  • Guo-Jing FU; Graduate School, Beijing University of Chinese Medicine Beijing 100029, China.
Zhongguo Zhong Yao Za Zhi ; 45(21): 5093-5102, 2020 Nov.
Article en Zh | MEDLINE | ID: mdl-33350224
ABSTRACT
To evaluate the efficacy and safety of Yangxue Qingnao Granules alone or combined with calcium channel blocker in treatment of migraine. In this study, four Chinese databases(CNKI, VIP, WanFang, CBM), three English databases(Cochrane Library, EMbase, Medline) and clinical trials registration center(ClinicalTrials.gov) were retrieved. The retrieval time was from the establishment of each database to January 8, 2020. According to the set inclusion criteria and exclusion criteria,the randomized controlled trial(RCT) of Yangxue Qingnao Granules alone or combined with calcium channel blocker was selected. The "Cochrane bias risk assessment" tool was used to evaluate the quality of the included studies. RevMan 5.3 was used to conduct Meta-analysis of the included studies and grade system was used to evaluate the evidence quality of the outcome indicators. A total of 583 documents were retrieved and finally included in 23 studies, with a total sample size of 2 308 cases, 1 171 cases in the treatment group and 1 137 cases in the control group. The overall quality of the research included was not high. Meta-analysis showed that,(1)in terms of effective rate, Yangxue Qingnao Granules combined with calcium channel blocker was better than calcium channel blocker(RR=1.24, 95%CI[1.17, 1.32], P<0.000 01), and there was no significant difference between Yangxue Qingnao Granules and calcium channel blocker(RR=1.36, 95%CI[0.91, 2.03], P=0.14).(2)In terms of reducing headache frequency, when the unit of headache frequency was times per month, Yangxue Qingnao Granules combined with calcium channel blocker was better than calcium channel blocker(MD=-1.39, 95%CI[-1.83,-0.95], P<0.000 01), when the unit of headache frequency was times daily, Yangxue Qingnao Granules combined with calcium channel blocker was better than calcium channel blocker(MD=-2.08, 95%CI[-2.34,-1.82], P<0.000 01).(3)In terms of headache intensity, when headache intensity was scored by pain intensity, Yangxue Qingnao Granules combined with calcium channel blocker was better than calcium channel blocker(MD=-0.70, 95%CI[-0.81,-0.59], P<0.000 01), when headache intensity was scored by VAS score, Yangxue Qingnao Granules combined with calcium channel blocker was better than calcium channel blocker(MD=-1.59, 95%CI[-2.13,-1.06], P<0.000 01).(4)In terms of reducing headache duration, Yangxue Qingnao Granules combined with calcium channel blocker was better than calcium channel blocker(SMD=-3.13, 95%CI[-4.12,-2.15], P<0.000 01). GRADE system showed that the evidence level of the above outcome indicators was low and extremely low. Twelve cases of adverse reactions were reported, all of which were mild. The results showed that the combination of Yang-xue Qingnao Granules can improve the effective rate, reduce the headache frequency, the headache intensity and the headache duration, and had good safety and low incidence of adverse reactions compared with the single calcium channel blocker. However, there was no difference in the effective rate between Yangxue Qingnao Granules alone and calcium channel blocker. In view of the low quality of this study, which affects the reliability of the conclusion, it is necessary to use the conclusion of this study carefully, and more high-quality randomized controlled trials are needed to further verify in the future.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicamentos Herbarios Chinos / Trastornos Migrañosos Tipo de estudio: Clinical_trials / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: Zh Revista: Zhongguo Zhong Yao Za Zhi Asunto de la revista: FARMACOLOGIA / TERAPIAS COMPLEMENTARES Año: 2020 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicamentos Herbarios Chinos / Trastornos Migrañosos Tipo de estudio: Clinical_trials / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: Zh Revista: Zhongguo Zhong Yao Za Zhi Asunto de la revista: FARMACOLOGIA / TERAPIAS COMPLEMENTARES Año: 2020 Tipo del documento: Article País de afiliación: China
...